World Journal of Gastroenterology · 2015 · 70 citations · 17 references
MedicineOncologyPathologyGastrointestinal OncologyMolecular OncologyOncogenesCancer BiomarkersCancer Molecular PathologyColorectal CancerMalignant NeoplasmsClinical Significance AssessmentColorectal Cancer BiomarkersColorectal Cancer DiagnosisColorectal Cancer PathologyColorectal Cancer PrognosisHer2 AmplificationHer2 ExpressionHuman Epidermal Growth Factor Receptor 2 (Her2) Expression
AIM: To detect the expression of COX-2 and HER-2 in colorectal cancer and to analyze their correlation and clinical significance. METHODS: A total of 1026 colorectal cancer surgical specimens were collected from patients treated from December 2002 to December 2007 at the First Affiliated Hospital of Anhui Medical University. All specimens were made into 4-μm slices. The expression of COX-2 and HER-2 were detected by immunohistochemistry using the streptavidin-biotin-peroxidase method. The correlations between COX-2 and HER-2 expression and colorectal cancer clinical features were analyzed. RESULTS: The positive rates of COX-2 and HER-2 expression in colorectal cancer were 77.97% (800/1026) and 46.20% (474/1026), respectively. There was a significant correlation between COX-2 and HER-2 expression in colorectal cancer (P < 0.05). In patients with tumor size ≥ 5 cm, the positive rates of COX-2 and HER-2 expression were 81.48% (308/378) and 57.94% (219/378), respectively. In patients with serosal invasion, the positive COX-2 and HER-2 expression rates were 80.53% (612/760) and 49.21% (374/760), respectively. In patients with lymph node metastasis, the positive expression rates were 85.04% (506/595) and 54.62% (325/595), respectively, and the positive expression rates differed significantly between patients with lymph node metastasis and those without (P < 0.05). In patients with Duke's C and D colorectal cancer, the positive COX-2 and HER-2 expression rates were 82.80% (443/535) and 57.94% (310/535), respectively. In patients with poorly differentiated colorectal cancer, the positive expression rates were 74.49% (210/282) and 52.84% (149/282), respectively (P < 0.05). In patients with distant metastasis, the positive expression rates were 82.27% (116/141) and 53.90% (76/141), respectively (P < 0.05). These findings suggest that COX-2 and HER-2 have synergistic effects in colorectal cancer. COX-2 and HER-2 expression had no significant correlation with sex, age, or tumor location. CONCLUSION: COX-2 and HER-2 are important markers for invasion and metastasis of colorectal cancer, and they act together to regulate the invasion and metastasis of colorectal cancer.
17
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Dara O. Kavanagh, Gillian Chambers, Liam O' Grady et al. · BMC Cancer · 2009 · 370 citations · Full text
Over-expression of COX-2 mRNA in colorectal cancer
Hennie M.J. Roelofs, René HM te Morsche, Bjorn WH van Heumen et al. · BMC Gastroenterology · 2014 · 229 citations · Full text
Regulation of Cyclooxygenase-2 pathway by HER2 receptor
Ratna K. Vadlamudi, Mahitosh Mandal, Liana Adam et al. · Oncogene · 1999 · 226 citations
Kaoru Kiguchi, Steve Carbajal, Keith Syson Chan et al. · PubMed · 2001 · 179 citations
Medicine, Cancer Biology, Oncology +17